Biodesix announces publication further validating the use of liquid biopsies and ngs techniques to provide clinical information for patients with cancer

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that new data were published in the peer-reviewed journal, diagnostics (basel), in an article titled, “analytic and clinical validation of a pan-cancer ngs liquid biopsy test for the detection of copy number amplifications, fusions and exon skipping variants.” this peer-reviewed publication further validates the genestrat ngs test and t
BDSX Ratings Summary
BDSX Quant Ranking